Emulate Inc.

Emulate Inc., a Boston-based biotechnology company specializing in organ-on-chip microphysiological systems, operates as a prime contractor supplying hardware, reagent kits, and maintenance services to federal research agencies across the Department of Health and Human Services, Department of Defense, and Department of Veterans Affairs. Emulate is a small business competing in full-and-open procurements with no set-aside designation predominating its recent awards, though several individual purchase orders carry Total Small Business set-aside designations.

The company's federal footprint centers on selling organ-on-chip culture modules, brain organoid platforms, and chip-based biological kits that replicate human organ functions for drug development, regulatory science, and alternatives-to-animal-testing research. Emulate's product line includes the Zoe Culture Modules (CM1, CM2, CM-2S configurations), Orb Hub Module systems, Chip-S1 Stretchable Chips, Chip-R1 Rigid Chips, and Liver-Chip kits configured for quad-culture models. Representative contract work includes a $354,235 Liver Human Emulation System supplied to the FDA in January 2022 under a total small business set-aside, a $217,700 upgrade to existing Zoe Culture Module Systems at the National Institute of Allergy and Infectious Diseases in August 2024, and a $248,000 order for Chip-S1 Basic Research Kits from the FDA in September 2025. Beyond product sales, Emulate provides preventative maintenance agreements, service agreements, and system repairs—a $205,554 extended warranty and service agreement with NIAID for organ-chip systems ran through March 2027, and a $160,704 Army Research, Development and Engineering Command contract for system maintenance and repair services extends to June 2025.

Customer concentration is pronounced and civilian-research-focused. The FDA dominates both award count and dollar volume (14 awards, $1.9 million combined potential value), followed by the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, and the Army Materiel Command's Research Development and Engineering Command. These top five customers account for 79 percent of Emulate's combined potential value across 47 awards. The company operates almost exclusively as a prime contractor (100% of awards); the source records zero subcontract activity.

Activity declined sharply after 2023. Emulate averaged seven to twelve awards annually from 2022 through 2023, then dropped to eight awards in 2024, three in 2025, and two in 2026 through early September. The company faces modest recompete exposure: three awards carrying combined potential value of $243,000 reach ultimate completion within the next twenty-four months. Combined obligated dollars ($9.7 million) exceed combined potential value ($4.9 million) by 198 percent, indicating drawdown against historical ceilings rather than growth in new award value.

On the grant side, Emulate received a cooperative agreement from the FDA's Center for Drug Evaluation and Research awarded September 2024 (completion August 2026) to develop and validate a human liver-chip system for predicting drug-induced liver injury in preclinical drug development. The award focuses on establishing a context-of-use claim for Emulate's quad-culture liver-chip, which the source indicates demonstrated 87 percent sensitivity and 100 percent specificity across eighteen small molecule drugs. This grant work anchors Emulate's federal positioning in regulatory science modernization alongside its product sales.

Emulate's NAICS profile splits across Analytical Laboratory Instrument Manufacturing (14 awards), Research and Development in Biotechnology Except Nanobiotechnology (13 awards), and Electronic and Precision Equipment Repair and Maintenance (5 awards), consistent with its role as both an equipment vendor and a research collaborator on organ-chip validation studies.